Oral Clostridium butyricum on mice endometritis through uterine microbiome and metabolic alternations

Endometritis occurs frequently in humans and animals, which can negatively affect fertility and cause preterm parturition syndrome. Orally administered Clostridium butyricum, a butyrate-producing gram-positive anaerobe, exhibits anti-inflammatory effects. However, the precise mechanism by which Clostridium butyricum attenuates endometritis remains unclear. This in vivo study evaluated the anti-inflammatory effects of orally administered Clostridium butyricum on uterine tissues. In addition, we conducted uterine microbiome and lipid metabolome analyses to determine the underlying mechanisms. Female Balb/c mice were divided into the following four groups (n = 5–20): (1) mock group, (2) only operation group (mice only underwent operation to exposed uterine horns from the side), (3) control group (mice underwent the same operation with the operation group + perfusion of lipopolysaccharide solution from uterine horns), and (4) Clostridium butyricum administration group (mice underwent the same operation with the control group + oral Clostridium butyricum administration from days 0 to 9). Clostridium butyricum was administered via oral gavage. On day 10, we investigated protein expression, uterine microbiome, and lipid metabolism in uterine tissues. Consequently, orally administered Clostridium butyricum altered the uterine microbiome and induced proliferation of Lactobacillus and Limosilactobacillus species. The effects can contribute to show the anti-inflammatory effect through the interferon-β upregulation in uterine tissues. Additionally, oral Clostridium butyricum administration resulted in the upregulations of some lipid metabolites, such as ω-3 polyunsaturated fatty acid resolvin D5, in uterine tissues, and resolvin D5 showed anti-inflammatory effects. However, the orally administered Clostridium butyricum induced anti-inflammatory effect was attenuated with the deletion of G protein-coupled receptor 120 and 15-lipooxgenase inhibition. In conclusion, Clostridium butyricum in the gut has anti-inflammatory effects on uterine tissues through alterations in the uterine microbiome and lipid metabolism. This study revealed a gut-uterus axis mechanism and provided insights into the treatment and prophylaxis of endometritis.

The uterus is not sterile, and a microbiome exists inside the uterus (Lozano et al., 2021).The commensal microbiome in the uterus contributes to many host physiological processes that maintain homeostasis by affecting the immune system and metabolic activities (Hooper et al., 2012).However, endometritis causes an imbalance in bacterial composition (dysbiosis) in the uterine microbiome (Moreno et al., 2016;Lozano et al., 2021), which triggers a host pro-inflammatory immune response and induces various inflammatory and metabolic diseases (Garrett et al., 2007;Vijay-Kumar et al., 2010;Elinav et al., 2011).Notably, dysbiosis of not only the vaginal microbiome but also the uterine microbiome affects pregnancy and birth rates (Moreno et al., 2016;Liu et al., 2019).
Systemic antibiotics are used to treat endometritis; however, their efficacy on the birth rate remains controversial (Cicinelli et al., 2015;Yoneda et al., 2016;Kuroda et al., 2021;Kato et al., 2022), and only limited therapies for the prevention and treatment of endometritis are available.Furthermore, similar to other organs, systemic antibiotics can affect physiological processes by altering the uterine microbiome alternations (Hagihara et al., 2020;Gao et al., 2023).Therefore, identifying alternative and safe ways to treat endometritis is important, since even partially effective therapies can increase birth rates.
Clostridium butyricum (ATCC 19398), a butyrate-producing gram-positive anaerobe, shows anti-inflammatory effects against endometritis when administered directly into the uterus (Mun et al., 2022).However, current probiotic dosing directly into the uterus is not realistic owing to technical issues in clinical situations, and the effects of orally administered C. butyricum on endometritis remain unclear.
Clostridium butyricum MIYAIRI 588 (CBM 588) has been used to treat gastrointestinal symptoms, such as diarrhea, as probiotics in Japan (Seki et al., 2003).Orally administered CBM 588 protects against intestinal necrosis and inflammation caused by antibiotic administration and Clostridioides difficile infection, by altering the gut microbiome and metabolic functions (Hagihara et al., 2018(Hagihara et al., , 2020(Hagihara et al., , 2021;;Ariyoshi et al., 2020Ariyoshi et al., , 2021)).Additionally, orally administered CBM 588 attenuates lung inflammation by upregulating lipid metabolites produced in the gut (Hagihara et al., 2022).Hence, oral CBM 588 administrations can show anti-inflammatory effects not only in the gut, but also in other tissues separate from the gut, such as the uterus.
Therefore, this in vivo study aimed to evaluate whether orally administered CBM 588 has anti-inflammatory effects in uterine tissues.In addition, we conducted uterine microbiome and lipid metabolome analyses to determine the underlying mechanisms.

Mice
Pathogen-free female Balb/c and C57BL/6 J mice (8-10 weeks) weighing approximately 20-23 g were used (Charles River Laboratories Japan, Inc., Yokohama, Japan).Gpr120 −/− mice (RBRC10195) and Irf-7 −/− mice (RBRC01420) were purchased from RIKEN BioResource Research Center.As previously described, the mice were provided with food and water ad libitum (Hagihara et al., 2022).This in vivo study was performed in accordance with the ARRIVE guidelines 2.0,1 American Veterinary Medical Association guidelines,2 and the Japanese College of Laboratory Animal Medicine's publication guide. 3The Ethics Committee of Aichi Medical University reviewed and approved this study (2023-58).

Pathologic evaluation
Harvested uterine tissues that were fixed with 10% neutralbuffered formalin were embedded in paraffin and cut into 3-μm sections, and stained with hematoxylin and eosin (H&E) for histological analysis via light microscopy (Hagihara et al., 2020).Uterine tissues were evaluated by a skilled pathologist.

Uterine microbiome analysis
Uterine microbiome analysis was conducted as described in our previous study (Hagihara et al., 2022), with minor modifications.Briefly, 100 μL PBS solution was perfused from one of two uterine horns with a microsyringe after tying the upper vagina tightly with a thread and the edge of the other side of uterine horn was cut.The PBS lavage fluid was used to characterize the microbiome composition of uterine tissues by sequencing the V3-V4 regions of the 16S rRNA gene.To extract DNA, the lavage fluid was suspended in 10 mM Tris-HCl and 10 mM EDTA buffer (pH 8.0), and added lysozyme (15 mg/mL; Sigma).After incubation at 37°C for 1 h, achromopeptidase (Wako) 4 Selleckchem.comwas added (2,000 U/mL) to the sample and incubated at 37°C for 30 min.As next step, SDS was added (1%) and mixed well.Then, proteinase K (Merck) was added (1 mg/mL) to the suspension and incubated at 55°C for 1 h.High-molecular mass DNA was isolated and purified by phenol/chloroform extraction, ethanol precipitation, and finally polyethylene glycol precipitation.For microbiome analysis, meta 16S rRNA gene sequencing PCR was performed by using Ex Taq Hot Start (TAKARA) and the Illumina forward primer 50-AATGATACGGCGACCACCGAGATCTACAC (adaptor sequence) + barcode (eight bases) + ACACTCTTTCCC TACACGAC GCTCTTCCGATCT (sequence primer) + CCTACGGGNG GCWGCA G-30 (341F) and the Illumina reverse primer 50-CAAGCAGAAGACG GCATACGAGAT (adaptor sequence) + barcode (eight bases) + GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT (sequence primer) + GACTACHVGGGTATCTAATCC-30 (805R) to amplify the hypervariable V3-V4 region of the 16S rRNA gene.Amplicons generated from each sample were subsequently purified using SPRI select (Beckman Coulter).The amount of DNA was quantified using the QuantiFluor dsDNA System and a Quantus Fluorometer (Promega).Mixed samples were prepared by pooling approximately equal amounts of each amplified DNA and sequenced using the MiSeq Reagent Kit V3 (600 cycle) and a MiSeq sequencer (Illumina), according to the manufacturer's instructions.The 16S rRNA sequence data generated by the MiSeq sequencer (Illumina) were processed using the quantitative insights into the microbial ecology (QIIME 2) pipeline as we previously published (Hagihara et al., 2022).Alpha-and β-diversity analysis were calculated using QIIME.An α-rarefaction curve was generated using the Chao 1 estimator of species richness.To compare the microbial composition between samples, β-diversity was measured by calculating the weighted UniFrac distances using QIIME default scripts.Principal coordinate analysis (PCoA) was applied to the resulting distance matrices of uterine microbiome at species level to generate two-dimensional plots.

Long-chain lipid metabolome analysis
Long-chain lipid metabolic analyses were conducted (Ariyoshi et al., 2020(Ariyoshi et al., , 2021;;Hagihara et al., 2022).Briefly, uterine tissues were sampled from the mice and immediately cryopreserved (stored at −80°C).The uterine tissues were lyophilized and 10 mg was weighed after ball milling.Methanol (180 μL) was added, and the mixture was vortexed for 1 min.We then used a Vanquish UHPLC system (Thermo Fisher Scientific), Q Exactive Focus (Thermo Fisher Scientific) with an electrospray ionization device, and liquid chromatography-tandem mass spectrometry (LC-MS/ MS) and Orbitrap LC-MS/MS analyses using an Acclaim RSLC120 C18 (Thermo Fisher Scientific) to conduct analysis.

Anti-inflammatory effects of orally administered Clostridium butyricum in uterine tissue
To determine whether CBM 588 has anti-inflammatory effects, we orally administered CBM 588 to mice with LPS-induced endometritis (Figure 1A).On day 10, we observed an upregulation of pro-inflammatory cytokines in the control group compared to the mock and operation groups (Figure 1B).Conversely, the CBM 588 administration group showed lower pro-inflammatory cytokines, such as TNF-α, IL-17A, IFN-γ, and IL-6, and higher anti-inflammatory cytokines, such as IL-10, TGF-β and IL-4, in the uterine tissues than those of the control group (Figure 1B; Supplementary Figure S1A).Moreover, among mice with endometritis, the weight gain of uterine tissues was significantly attenuated by CBM 588 administration (Figure 1C), whereas the body weights and survival rates did not show significant differences between the control and CBM 588 groups (Supplementary Figures S1B,C).These findings and historical evaluations suggest that CBM 588 can elicit anti-inflammatory effects in uterine tissues by attenuating the inflammatory symptoms caused by endometritis (Figure 1D).

Effect of oral Clostridium butyricum on uterine microbiome
To reveal the effect of CBM 588 on uterine microbiomes, we performed uterine microbiome analysis among the control and CBM 588 administration group on day 10 (Figure 2A).The bar graphs depict the mean relative abundance of bacterial groups at the phylum to family levels (Figure 2B; Supplementary Figure S2A).CBM 588 administration did not significantly alter the relative abundances of each bacterial group at phylum and class levels compared to the control group (Supplementary Figure S2A).Additionally, CBM 588 administration did not significantly change α-diversity and β-diversity in the uterine microbiome compared with the control group (Supplementary Figures S2B,C).However, at the order and family levels, respectively, the CBM 588 administration group had significantly higher relative abundances of only Lactobacillales and Lactobacillaceae, compared with the control group (Figures 2C,D).Additionally, at the genus level, Lactobacillus, Ligilactobacillus, and Limosilactobacillus were detected in the Lactobacillaceae group, and the CBM 588 administration group had significantly higher relative abundance of Lactobacillus and Limosilactobacillus than the control group (Figure 2E), whereas the other groups did not show the significantly differences.

Supernatant of Clostridium butyricum promotes Lactobacillus spp. and Limosilactobacillus spp. proliferations
We conducted an in vitro study to determine the effects of CBM 588 on the proliferation of Lactobacillus and Limosilactobacillus spp.(Figure 3A).We evaluated seven species (eight strains) that were frequently detected in the organs of the genus organs (Haakensen   3B,C).They showed significantly enhanced proliferations in the GAM broth after 24 h incubation anaerobically, even though the bacterial suspensions were containing only 1% of the CBM 588 culture medium supernatant.Among the eight isolates, L. reuteri showed the highest ratio of the bacterial concentrations (bacteria suspensions containing CBM 588 supernatants at 1, 5, and 10% /bacterial suspensions without CBM 588 supernatants [0%]) (Supplementary Figure S3A).

Orally administered Clostridium butyricum shows anti-inflammatory effects through the interferon-β upregulation in uterine tissues
Lactobacillus spp.and Limosilactobacillus spp.upregulated type I IFNs and enhanced bacterial clearances (Redanz and Kriegel, 2022;Sekheri et al., 2022;Wang L. et al., 2023).Hence, we detected IFN-β production in uterine tissue, and we found the upregulation of IFN-β after oral CBM 588 administrations (Figures 4A,B).Additionally, to determine the effects of type I IFNs on the anti-inflammatory effects of orally administered CBM 588 in uterine tissues, we conducted an in vivo study using Irf-7 gene knock out (KO) mice (Figure 4C).Consequently, the anti-inflammatory effects of CBM 588 were attenuated (Figure 4D).Then, the CBM 588 (IRF-7 KO) group showed higher pro-inflammatory cytokines, such as TNF-α, IL-17A, IFN-γ, and IL-6, and lower anti-inflammatory cytokines, such as IL-10, TGF-β, and IL-4, in the uterine tissues than those of the CBM 588 group (Figure 4D; Supplementary Figure S4A), thereby exaggerating uterine tissue inflammation with the inhibition of type I IFNs productions.Moreover, compared to the CBM 588 group, the weight gain of uterine tissues was significantly increased by the inhibition of type I IFNs production (Figure 4E), whereas body weights and survival rates did not show significant differences between the CBM 588 group and CBM 588 (IRF-7 KO) group (Supplementary Figures S4B,C).Results are presented as mean ± standard deviation.Each dot represents a single sample.The results were considered statistically significant when the differences were p < 0.05, as determined using one-way ANOVA (B,C).See also Supplementary Figure S3.CBM 588, Clostridium butyricum MIYAIRI 588.Hagihara et al. 10.3389/fmicb.2024.1351899Frontiers in Microbiology 07 frontiersin.org

Orally administered Clostridium butyricum shows anti-inflammatory effects through G protein-coupled receptor 120
We conducted an in vivo study to reveal the mechanisms of orally administered CBM 588 in uterine tissues (Figure 6A).To inhibit the effects of resolvin D5, we used G-protein-coupled receptor 120 (GPR120)-expressing genes KO mice and a 15-LOX inhibitor (PD146176).In results, resolvin D5 administration showed antiinflammatory effects similar to those of CBM 588.However, GPR 120 KO mice and the 15-LOX inhibitor attenuated the anti-inflammatory effects of orally administered CBM 588 (Figure 6B).The impacts of GPR 120 deletion on CBM 588 induced anti-inflammatory effects was greater than that of the 15-LOX inhibitor.We also found that orally administered CBM 588 showed greater anti-inflammatory effects than the C. butyricum reference isolate (ATCC 19398), although the differences were not significant.Additionally, the GPR 120 deletion and 15-LOX inhibitor did not decrease IFN-β productions with orally CBM 588 administrations (Figure 6C).The weight gain of uterine tissues tended to increase with GPR 120 deletion and 15-LOX inhibition (Figure 6D).Conversely, body weight showed a decreasing tendency, but there were no significant differences between the CBM 588 groups and the other groups.

Discussion
In this study, we described a gut-uterine tissue axis mechanism.Orally administered CBM 588 altered uterine microbiome and induced the upregulation of some lipid metabolites, such as ω-3 PUFA resolvin D5, in uterine tissues.These effects can contribute to the antiinflammatory effects through the IFN-β upregulation and GPR120 activation in uterine tissues (Figure 7).
Clostridium butyricum (ATCC 19398) showed anti-inflammatory effects in mice with endometritis when administered directly into the uterine tissues, resulting in an improvement in the birth rate of mice (Mun et al., 2022).In this in vivo study, we observed anti-inflammatory effects in the uterine tissues, even though CBM 588 was orally administered to mice with endometritis.These findings suggest that CBM 588 can be used to prevent and treat endometritis through noninvasive oral administration.
The commensal microbiome of the host plays an important role in maintaining homeostasis by modulating the host immune system and metabolic functions (Garrett et al., 2007;Vijay-Kumar et al., 2010;Elinav et al., 2011;Hooper et al., 2012).In our microbiome analysis of the uterine tissues, oral administration of CBM 588 altered the uterine microbiome in mice with endometritis and increased the relative abundance of Lactbacillus spp.Limosilactobacillus spp.are among the major species in the microbiome of healthy volunteers (Moreno et al., 2016;Chen et al., 2017;Lozano et al., 2021).Lactobacillus spp.and Limosilactobacillus spp.have the potential to alleviate inflammatory diseases through the inhibition of the inflammatory factors in the NF-κB and MAPKs signaling pathway (Qin et al., 2009;Peter et al., 2018;Liu et al., 2022;Zong et al., 2023).Furthermore, these species show the anti-inflammatory effects with the upregulation of type I IFNs (Bourgeois et al., 2011).Then, interferon regulation factor (IRF)-7 plays an important role in the host defense against bacterial infection by regulating IFN-β (Qing and Liu, 2023).Additionally, oral administration of CBM 588 enhanced type I and III IFNs in lung tissues through IRF-1/−7 activation, and IRF-7 affected IFNs production more effectively than IRF-1 in our previous in vivo study (Hagihara et al., 2022).Hence, we expected that, similar with lungs, uterine tissues were also affected with CBM 588 to produce IFN-β and attributed to show the anti-inflammatory effects.Consequently, we admitted the upregulation of IFN-β in uterine tissues with oral CBM 588 administration and attenuations of the CBM 588 induced anti-inflammatory effects in IRF-7 KO mice.Furthermore, oral administration of CBM 588 significantly promoted resolvin D5 production in the uterine tissues of mice with endometritis, and the lipid metabolite shows antiinflammatory effects as specialized pro-resolving mediators (SPMs) (Perry et al., 2020).Consequently, inhibitions of some lipid metabolite productions, including ω-3 PUFA resolvin D5, with 15-LOX inhibitor and diminished GPR120 expression attenuated the anti-inflammatory effects of orally administered CBM 588 in uterine tissues, whereas we did not make sure that 15-LOX inhibitor and diminishment of GPR120 would downregulate the resolvin D5 production in the CBM 588 treated mice.Therefore, we expected that orally administered CBM 588-induced resolvin D5 would play an important role in the anti-inflammatory effects in uterine tissues.Additionally, IFN-β treatments accelerates clearance of bacteria, and accelerates resolution of inflammation with concomitant increases in SPMs such as resolvin D5 (Sekheri et al., 2022).Hence, we expected that CBM 588-induced IFN-β would also contribute to promote the resolvin D5 production to show anti-inflammatory effects in uterine tissues.However, this study has some limitations.First, we did not clarify the precise mechanisms by which CBM 588 increases Lactobacillus spp.and Limosilactobacillus spp., although we confirmed that CBM 588 is related to their proliferation.Second, to evaluate the antiinflammatory effects of CBM 588 on uterine tissues, we used a 15-LOX inhibitor and GPR120 KO mice.However, the 15-LOX inhibitor is not specific to resolvin D5 production, which affects the production of other lipid mediators, and has anti-inflammatory effects (Perry et al., 2020).Additionally, GPR120 is the main ligand for ω-3 unsaturated fatty acid receptor and it is not specific to only resolvin D5 (Chiang et al., 2012;Husted et al., 2017).Hence, our results suggest the possibilities that other lipid mediators may play important roles in these effects.Related to the limitation, we did not confirm that the absence of GRP120 or IRF-7 genes inhibits the resolvin D5-induced anti-inflammatory effects on the uterine tissue or not.Hence, further study to clear the relationships between GRP120 or IRF7 genes and resolvin D5-induced anti-inflammatory effects are needed.Thirdly, CBM588 has anti-inflammatory effects in the lung since the increase of IFN-λs through the upregulation of lipid metabolites and GPR120 activation (Hagihara et al., 2022).However, compared to the type I IFNs, IFN-λs (type III) have not cleared the roles for the responses to the inflammation in uterine tissues.Hence, we focused on the role of type I IFNs in this study.Additionally, among the GRP120 KO mouse, IFN-β production was not inhibited but increased in mice treated with CBM588, compared to the control group.We expected that this result derives from the facts that there are some mechanisms to stimulate IFNs productions (Lazear et al., 2015).However, we could not reveal the precise mechanism in this study.Hence, further study is needed to clear the precise mechanism and roles of CBM 588-induced IFN-λ in uterine tissues with inflammations.Finally, the human microbiome differs from the mice microbiome (Human Microbiome Project Consortium, 2012).Further studies are required to investigate whether these results can be replicated in humans.

Conclusion
In summary, orally administered CBM 588 showed antiinflammatory effects in the uterine tissues.Orally administered CBM 588 affected the uterine microbiome, and the relative abundances of Lactobacillus spp.and Limosilactobacillus spp.were upregulated.These changes can lead to the upregulation of IFN-β and altered host lipid metabolic functions in uterine tissues.Notably, the antiinflammatory lipid metabolite resolvin D5 in uterine tissues was upregulated by oral CBM 588 administrations.However, the antiinflammatory effects derive from oral CBM 588 administration was attenuated with the deletion of GPR 120 and 15-LOX inhibition.Our results reveal a gut-uterine tissue axis mechanism and provide novel insights into targets for endometritis treatment and prophylaxis.informed consent was obtained from owners for the participation of their animals in this study.

FIGURE 1
FIGURE 1 Anti-inflammatory effects of orally administered Clostridium butyricum in uterine tissue.(A) Balb/c mice were divided into 4 groups.Mock group received no treatments; only operation group, control group and CBM 588 group received operations on days 0 and 5. Control group and CBM 588 group conducted LPS perfusions from the uterus horns.Only CBM 588 groups received oral CBM 588 administrations from days 0 to 9. (B) Cytokine levels in uterine tissues on day 10 (n = 9 or 10).(C) Weights of uterine tissues (n = 9 or 19) and colon tissues (n = 9).(D) Representative histological images of uterine tissues on day 10 (scale bar, 100 mm, bottom right).Results are presented as mean ± standard deviation.Each dot represents a single mouse.The results were considered statistically significant when the differences were p < 0.05, as determined using one-way ANOVA (B,C).See also Supplementary Figure S1.CBM 588, Clostridium butyricum MIYAIRI 588; LPS, lipopolysaccharide.

FIGURE 2
FIGURE 2 Effect of oral C. butyricum on uterine microbiome.(A) Balb/c mice were divided into 2 groups.Control group (n = 4) and CBM 588 group (n = 4) received operations on days 0 and 5. Control group and CBM 588 group conducted LPS perfusions from the uterus horns.Only CBM 588 group received oral CBM 588 administrations from days 0 to 9. (B) Bacterial composition in uterine tissues at the family level.(C) Relative abundances of Lactobacillales in uterine microbiome at order level.(D) Relative abundances of Lactobacillaceae in uterine microbiome at family level.(E) Relative abundances of Lactobacillus, Ligilactobacillus, and Limosilactobacillus in uterus microbiome at genera level.Results are presented as mean ± standard deviation.Each dot represents a single mouse.Results were considered statistically significant when the differences were p < 0.05, as determined by Student's t-test (C-E).See also Supplementary Figure S2.CBM 588, Clostridium butyricum MIYAIRI 588; LPS, lipopolysaccharide.

FIGURE 4
FIGURE 4 Orally administered C. butyricum shows anti-inflammatory effects through the interferon-β upregulation in uterine tissues.(A) Balb/c mice were divided 3 groups.Mock group received no treatment (n = 8), control group (n = 8) and CBM 588 group (n = 8) received operations on day 0 and 5.Then, control group and CBM 588 group conducted LPS perfusions from uterus horns.Only CBM 588 group received orally CBM 588 administrations from days 0 to 9. (B) IFN-β level in uterine tissues on day 10.(C) C57BL/6 J mice were divided into control group (n = 5), CBM 588 group (n = 5) and CBM 588 (IRF-7 KO) group (n = 5).They received operations on day 0 and 5, and then, conducted LPS perfusions from uterus horns.Two groups in the back received oral CBM 588 administrations from day 0 to 9. (D) Cytokine levels in uterine tissues on day 10.(E) Weights of uterine tissues and colon on day 10.Results are presented as mean ± standard deviation.Each dot represents a single mouse.Results were considered statistically significant when the differences were p < 0.05, as determined by one-way ANOVA (B-E).See also Supplementary Figure S4.CBM 588, Clostridium butyricum MIYAIRI 588; LPS, lipopolysaccharide; IFN-β, interferon-β; IRF-7, interferon regulation factor-7.

FIGURE 5
FIGURE 5 Orally administered C. butyricum alters lipid metabolism in uterine tissues.(A) Balb/c mice were divided into 2 groups.The control group (n = 4) and CBM 588 group (n = 4) received operations on days 0 and 5.The control group and CBM 588 group conducted LPS perfusions from the uterus horns.Only the CBM 588 group received oral CBM 588 administrations from days 0 to 9. (B) LDA Score (Log2) of lipid metabolites in uterine tissues when compared with the control and CBM 588 administration group.(C) Peak areas of DHA, resolvin D5 and 13,14-dyhydro-15-keto PGF2α in uterine tissues.Results are presented as mean ± standard deviation.Each dot represents an individual mouse.Results were considered statistically significant when differences were p < 0.05 by Student's t-test (C).See also Supplementary Figure S5.CBM 588, Clostridium butyricum MIYAIRI 588; LPS, lipopolysaccharide.

FIGURE 6
FIGURE 6 Orally administered C. butyricum shows anti-inflammatory effects through G protein-coupled receptor 120.(A) Balb/c mice were divided into 6 groups (n = 5, respectively).All groups received operations on days 0 and 5, and then, conducted LPS perfusions from the uterus horns.CBM 588 group, CBM 588 + 15-LOX inhibitor group and CBM 588 (GPR120 KO) group received oral CBM 588 administrations from days 0 to 9. ATCC 19398 group received oral C. butyricum ATCC 19398 administrations from days 0 to 9. Resolvin D5 group received resolving D5 intraabdominally from day 0 to 9. (B) TNF-α level in uterine tissues on day 10.(C) IFN-β level in uterine tissues on day 10.(D) Weights of uterus tissues, colon and mouse body.Results are presented as mean ± standard deviation.Each dot represents a single mouse.Results were considered statistically significant when the differences were p < 0.05, as determined by one-way ANOVA (B-D).CBM 588, Clostridium butyricum MIYAIRI 588; LPS, lipopolysaccharide; IFN-β, interferon-β.